FSD Pharma has filed an IND (Investigational New Drug Application) with the FDA for the use of its drug FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19. The randomized, controlled, double-blind trial is set to take place at 25-30 hospitals in the U.S. Yourway offers global direct-to-patient trial service 24/7, including during the COVID-19 crisis. As a premium drug product shipments courier, we reduce our client’s timelines with faster response times and agile transport operations.
6681 Snowdrift Road
Toll Free:
Fax:
Email:
